Chagas Disease-Pipeline Review, H1 2017

Chagas Disease-Pipeline Review, H1 2017


  • Products Id :- GMDHC9253IDB
  • |
  • Pages: 83
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Chagas Disease-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chagas Disease-Pipeline Review, H1 2017, provides an overview of the Chagas Disease (Infectious Disease) pipeline landscape.

Chagas disease or American Trypanosomiasis is a vector-borne anthropozoonosis caused by the protozoan parasite Trypanosoma cruzi. Symptoms include swelling at the infection site, fever, fatigue, body aches, loss of appetite, nausea, diarrhea or vomiting and swollen glands. Treatment includes antiparasitic medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chagas Disease-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chagas Disease (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chagas Disease (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Chagas Disease (American Trypanosomiasis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 3, 4 and 6 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 17 and 4 molecules, respectively.

Chagas Disease (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Chagas Disease (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Chagas Disease (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Chagas Disease (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Chagas Disease (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Chagas Disease (Infectious Disease)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Chagas Disease (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Chagas Disease (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Chagas Disease (American Trypanosomiasis)-Overview

Chagas Disease (American Trypanosomiasis)-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Chagas Disease (American Trypanosomiasis)-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Chagas Disease (American Trypanosomiasis)-Companies Involved in Therapeutics Development

AstraZeneca Plc

Bayer AG

Daiichi Sankyo Company Ltd

Eisai Co Ltd

GlaxoSmithKline Plc

Grupo Praxis Pharmaceutical SA

KaloBios Pharmaceuticals Inc

Kancera AB

Novartis AG

Oblita Therapeutics BVBA

Sanofi

Chagas Disease (American Trypanosomiasis)-Drug Profiles

benznidazole-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

benznidazole-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

chagas disease (bivalent) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

chagas disease vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

chagas disease vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chagas disease vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cz-007-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cz-008-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

D-121-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EPLBS-1246-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EPLBS-967-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fexinidazole-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fosravuconazole-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GNF-6702-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

K-777-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KAN-0441411-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MAO-1-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NEU-321-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nifurtimox-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nifurtimox SR-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAR-114137-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Chagas Disease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Cruzipain for Chagas Disease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit SOD for Chagas Disease and Leishmaniasis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Chagas Disease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Chagas Disease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Chagas Disease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Chagas Disease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Infectious Diseases-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Infectious Diseases-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Leishmaniasis and Chagas Disease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Cruzipain for Chagas Disease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Lanosterol 14 alpha-Demethylase for Chagas Disease, Leishmaniasis and African Trypanosomiasis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Proline Racemase for Chagas Disease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VNI-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chagas Disease (American Trypanosomiasis)-Dormant Projects

Chagas Disease (American Trypanosomiasis)-Discontinued Products

Chagas Disease (American Trypanosomiasis)-Product Development Milestones

Featured News & Press Releases

Apr 06, 2017: Benznidazole on Track in Progress to IND and NDA Submissions

Jan 05, 2017: KaloBios Announces Positive Guidance from FDA for Benznidazole

Dec 12, 2016: KaloBios Completes Meeting with FDA for Benznidazole

Nov 15, 2016: Bayer to Fight Chagas Disease in Children

Aug 08, 2016: A single compound could treat three parasitic diseases

Apr 11, 2016: KaloBios Announces New Product Pricing Model

Jul 27, 2015: NIH helps UC San Diego researchers repurpose Sanofi pain drug for tropical disease

May 07, 2015: UTMB researchers devise vaccine that provides long-term protection against Chagas disease

Dec 26, 2013: New Drug Candidates Show Promise for Cure for Chagas Disease

Nov 14, 2013: Drug Trial for Leading Parasitic Killer of the Americas Shows Mixed Results but Provides New Evidence for Improved Therapy

May 03, 2013: Funding boost for GSK's open innovation research into diseases affecting the developing world

Apr 30, 2012: NYU School of Medicine Receives Support From The Tres Cantos Open Lab Foundation To Discover New Drugs Against Chagas Disease

Mar 12, 2012: DNDi Receives 2m Strategic Translation Award From Wellcome Trust To Develop New Drug Against Chagas Disease

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development for Chagas Disease (American Trypanosomiasis), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Chagas Disease (American Trypanosomiasis), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Universities/Institutes, H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Chagas Disease (American Trypanosomiasis)-Pipeline by AstraZeneca Plc, H1 2017

Chagas Disease (American Trypanosomiasis)-Pipeline by Bayer AG, H1 2017

Chagas Disease (American Trypanosomiasis)-Pipeline by Daiichi Sankyo Company Ltd, H1 2017

Chagas Disease (American Trypanosomiasis)-Pipeline by Eisai Co Ltd, H1 2017

Chagas Disease (American Trypanosomiasis)-Pipeline by GlaxoSmithKline Plc, H1 2017

Chagas Disease (American Trypanosomiasis)-Pipeline by Grupo Praxis Pharmaceutical SA, H1 2017

Chagas Disease (American Trypanosomiasis)-Pipeline by KaloBios Pharmaceuticals Inc, H1 2017

Chagas Disease (American Trypanosomiasis)-Pipeline by Kancera AB, H1 2017

Chagas Disease (American Trypanosomiasis)-Pipeline by Novartis AG, H1 2017

Chagas Disease (American Trypanosomiasis)-Pipeline by Oblita Therapeutics BVBA, H1 2017

Chagas Disease (American Trypanosomiasis)-Pipeline by Sanofi, H1 2017

Chagas Disease (American Trypanosomiasis)-Dormant Projects, H1 2017

Chagas Disease (American Trypanosomiasis)-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

AstraZeneca Plc, Bayer AG, Daiichi Sankyo Company Ltd, Eisai Co Ltd, GlaxoSmithKline Plc, Grupo Praxis Pharmaceutical SA, KaloBios Pharmaceuticals Inc, Kancera AB, Novartis AG, Oblita Therapeutics BVBA, Sanofi

Chagas Disease (American Trypanosomiasis) Therapeutic Products under Development, Key Players in Chagas Disease (American Trypanosomiasis) Therapeutics, Chagas Disease (American Trypanosomiasis) Pipeline Overview, Chagas Disease (American Trypanosomiasis) Pipeline, Chagas Disease (American Trypanosomiasis) Pipeline Assessment

select a license
Single User License
USD 2000 INR 143800
Site License
USD 4000 INR 287600
Corporate User License
USD 6000 INR 431400

NEWSLETTER BY CATEGORY




Testimonials

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com